

Sun Pharma Advanced Research Company Ltd.
17/B, Mahal Industrial Estate,
Mahakali Caves Road,
Andheri (East), Mumbai 400 093 India
Tel.: (91-22) 6645 5645
Fax.: (91-22) 6645 5685



FOR IMMEDIATE RELEASE

SPARC Announces India Approval for Paclitaxel Injection Concentrate for Nanodispersion (PICN)

January 23, 2014, Mumbai: Sun Pharma Advanced Research Company Ltd. (SPARC) (Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872) announced that its licensee has received an approval from the Drug Controller General of India (DCGI) for Paclitaxel Injection Concentrate for Nanodispersion (PICN), indicated for the treatment of metastatic breast cancer.

In a clinical study in metastatic breast cancer patients, PICN was found to be equally effective and safe when compared to ABRAXANE[®]. PICN is approved in India for both 260mg/m² and 295mg/m² doses to be administered every 3 weeks.

PICN is a novel formulation of Paclitaxel using SPARC's proprietary Nanotecton[™] platform technology and is a Cremophor[®] and Albumin-free formulation. It offers the convenience of a quick and easy one-step dilution and infusion preparation for healthcare professionals. PICN can be administered in a short 30 minute infusion and unlike conventional Paclitaxel formulations it does not require premedication with steroids and anti-histamines and does not lead to any significant hypersensitivity reaction in patients.

SPARC has licensed Sun Pharmaceutical Industries Ltd. (SPIL) or its assignee to manufacture, promote and distribute PICN in the Indian market. As a part of the arrangement, SPARC is eligible for milestone and royalty income.

*Cremophor[®] is the registered trademark of BASF Aktiengesellschaft.
ABRAXANE[®] is a registered trademark of Abraxis BioScience, LLC.*

About SPARC

Sun Pharma Advanced Research Company Ltd. (SPARC) is an international pharmaceutical company engaged in research and development of drugs and delivery systems. More information about the company can be found at www.sunpharma.in.

Contact

Nimish Desai
Tel +91 22 6645 5645, Ext 5717
Tel Direct +91 22 66455717
Mobile +91 98203 30182
Email: nimish.desai@sunpharma.com

Mira Desai
Tel +91 22 6645 5645, Ext 5606
Tel Direct +91 22 66455606
Mobile +91 98219 23797
Email: miradesai@sunpharma.com